Shintaro Yamanaka1, Masao Miyagawa2, Yoshifumi Sugawara3, Shinji Hasebe4, Tomomi Fujii4,5, Kazuto Takeuchi4, Keiko Tanaka6,7, Yoshihiro Yakushijin8,9. 1. Ehime University School of Medicine, Toon, Ehime, Japan. 2. Department of Radiology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. 3. Department of Diagnostic Radiology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan. 4. Cancer Center, Ehime University Hospital, Toon, Ehime, Japan. 5. Department of Clinical Oncology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. 6. Department of Epidemiology and Preventive Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. 7. Research Promotion Unit, Translation Research Center, Ehime University Hospital, Toon, Ehime, Japan. 8. Cancer Center, Ehime University Hospital, Toon, Ehime, Japan. yoshiyak@m.ehime-u.ac.jp. 9. Department of Clinical Oncology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. yoshiyak@m.ehime-u.ac.jp.
Abstract
BACKGROUND: Positron Emission Tomography-Computed Tomography (PET-CT) has been changing diagnostic and therapeutic strategies for patients with cancers, and several PET-CT-related prognostic factors have been reported. We have focused on metabolic tumor volumes (MTVs) over the whole body and in specific organs using 18F-PET-CT imaging, and have compared clinical data to know the prognosis of patients with diffuse large B cell lymphoma (DLBCL). PATIENTS AND METHODS: From January 2006 to December 2016, patients who were newly diagnosed for de novo DLBCL and who received 18F-FDG PET-CT scans for disease staging at Ehime University Hospital were reviewed. RESULTS: A total of forty out of 108 patients with DLBCL were analyzed. The median and the average follow-up were 3.9 years and 3.6 years. Both MTV50 and MTV60 whole-body searching indicated effective prognostic values for patients with DLBCL statistically (P = 0.027). However, analysis of MTVs in the spleen and in bone marrow did not provide any prognostic value. Receiver operating characteristic (ROC) analysis indicated that the cutoff level 25.8 in MTV60 is the most effective prognostic value (P = 0.022) which predicts patient survival after treatment with R-CHOP chemotherapy. CONCLUSION: MTV60 using whole-body scanning appears to be an effective indicator in DLBCL and indicates the patient prognosis.
BACKGROUND: Positron Emission Tomography-Computed Tomography (PET-CT) has been changing diagnostic and therapeutic strategies for patients with cancers, and several PET-CT-related prognostic factors have been reported. We have focused on metabolic tumor volumes (MTVs) over the whole body and in specific organs using 18F-PET-CT imaging, and have compared clinical data to know the prognosis of patients with diffuse large B cell lymphoma (DLBCL). PATIENTS AND METHODS: From January 2006 to December 2016, patients who were newly diagnosed for de novo DLBCL and who received 18F-FDG PET-CT scans for disease staging at Ehime University Hospital were reviewed. RESULTS: A total of forty out of 108 patients with DLBCL were analyzed. The median and the average follow-up were 3.9 years and 3.6 years. Both MTV50 and MTV60 whole-body searching indicated effective prognostic values for patients with DLBCL statistically (P = 0.027). However, analysis of MTVs in the spleen and in bone marrow did not provide any prognostic value. Receiver operating characteristic (ROC) analysis indicated that the cutoff level 25.8 in MTV60 is the most effective prognostic value (P = 0.022) which predicts patient survival after treatment with R-CHOP chemotherapy. CONCLUSION: MTV60 using whole-body scanning appears to be an effective indicator in DLBCL and indicates the patient prognosis.
Entities:
Keywords:
18F-FDG-PET; Diffuse large B cell lymphoma; MTV; SUV
Authors: Frédérique St-Pierre; Stephen M Broski; Betsy R LaPlant; Kay Ristow; Matthew J Maurer; William R Macon; Thomas M Habermann; Stephen M Ansell; Carrie A Thompson; Ivana N M Micallef; Grzegorz S Nowakowski; Thomas E Witzig Journal: Am J Hematol Date: 2019-05-16 Impact factor: 10.047
Authors: Jorge E Jimenez; Dong Dai; Guofan Xu; Ruiyang Zhao; Tengfei Li; Tinsu Pan; Linghua Wang; Yingyan Lin; Zhangyang Wang; David Jaffray; John D Hazle; Homer A Macapinlac; Jia Wu; Yang Lu Journal: Clin Nucl Med Date: 2022-03-01 Impact factor: 7.794